Innovation Theater Breakfast (non-accredited/non-approved for CECH): EscharEx®: Innovative Multimodal Enzymatic Debridement for Chronic Wounds

Sponsored by MediWound Ltd.

EscharEx® is a novel biological drug composed of a concentrate of proteolytic enzymes enriched in bromelain, derived from the stem of the pineapple plant. Its unique enzymatic composition enables fast and effective debridement of wounds containing various forms of denatured proteins and non-viable tissue.

The same active ingredient is also used in NexoBrid®, a medicinal product approved in the EU, US, and Japan for the removal of eschar in adult and pediatric patients with deep partial- and full-thickness burns.

In vitro and preclinical studies have provided insights into the multimodal mechanism of action of EscharEx, supporting its therapeutic potential across a range of wound types. Phase II randomized controlled trials in venous leg ulcers (VLU), diabetic foot ulcers (DFU), and traumatic wounds have demonstrated EscharEx’s consistent efficacy in wound debridement, promotion of granulation tissue, and reduction of bioburden and biofilm.

These promising results have led to the launch of a global Phase III study - the VALUE trial, designed to evaluate the efficacy of EscharEx in wound bed preparation and facilitation of closure in patients with VLU. A Phase II/III study in DFU is currently in development.

This breakfast symposium will highlight EscharEx’s unique mechanism of action, review key findings from previous clinical trials, share specific case studies in VLU and DFU, and provide updates on the design and progress of ongoing and planned clinical trials.